Repurposing validated biology to rescue immuno-metabolic pathways.
Revisioning Bio develops therapeutic programs for diseases where immune activation, aging, metabolic stress, and mitochondrial dysfunction impair cellular energy, repair, and resilience.
We build rational combinations designed to correct disrupted pathway biology.
Interactive biology map
A pathway-level view of inflammation, metabolism, depression biology, and the gut-brain axis.
How we turn pathway biology into programs.
Each program starts with a disrupted biological circuit, then pairs validated assets with biomarkers that show whether the circuit is moving back toward repair.
Map the disrupted circuit
Identify where inflammatory signaling, nutrient flow, mitochondrial function, and tissue repair break down.
Start from validated assets
Prioritize clinical-stage or biologically validated therapies with evidence that can shorten translational risk.
Design the combination
Pair assets that lower the disease-driving signal with inputs that support energy production and repair.
Measure pathway engagement
Use biomarkers to select patients, confirm biological response, and focus capital on programs with clear signal.
A capital-efficient path from overlooked assets to focused programs.
Building pathway-rescue combinations for diseases of cellular energy failure.
Revisioning Bio is actively partnering to advance repurposed therapeutics through immuno-metabolic biology, rational combination design, and precision biomarkers.
Alex Michaels
Alex Michaels is a finance-trained biotechnology strategist focused on business development. His work is built around a core belief: in a capital-intensive industry, every marginal dollar must be leveraged intelligently
Alex’s experience spans CAR-T supply chain operations at a leading biotechnology company, repurposed therapeutics, antibody-drug conjugate delivery, metabolic pathway modulation, and advanced delivery platforms. He focuses on identifying underutilized assets, university technologies, and prior scientific efforts that may have failed for reasons of timing, delivery, indication selection, or capital strategy — and repositioning them for renewed commercial success.
He started LicenseRx, a business development intelligence platform built to identify overlooked university technologies and translate them into investable biotech opportunities. Through LicenseRx, Alex leverages university relationships and a seasoned executive network that includes leaders across artificial intelligence, banking, pharmaceutical development, and business development.
Alex also serves as a strategic advisor to WaterPure Inc., where he supports the expansion of novel technology into high-value industrial markets, including pharmaceutical manufacturing. His work centers on connecting science, capital, and industry demand to turn underutilized technologies into commercially compelling opportunities.